Shield Therapeutics Statistics

Total Valuation

Shield Therapeutics has a market cap or net worth of GBP 18.57 million. The enterprise value is 27.97 million.

Market Cap	18.57M
Enterprise Value	27.97M

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Shield Therapeutics has 782.06 million shares outstanding. The number of shares has increased by 59.90% in one year.

Current Share Class	n/a
Shares Outstanding	782.06M
Shares Change (YoY)	+59.90%
Shares Change (QoQ)	+5.37%
Owned by Insiders (%)	2.49%
Owned by Institutions (%)	25.57%
Float	387.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.07
PB Ratio	43.44
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.98
EV / Sales	1.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.69

Financial Position

The company has a current ratio of 1.05, with a Debt / Equity ratio of 36.91.

Current Ratio	1.05
Quick Ratio	0.90
Debt / Equity	36.91
Debt / EBITDA	n/a
Debt / FCF	-0.96
Interest Coverage	-16.41

Financial Efficiency

Return on equity (ROE) is -261.66% and return on invested capital (ROIC) is -79.25%.

Return on Equity (ROE)	-261.66%
Return on Assets (ROA)	-47.85%
Return on Capital (ROIC)	-79.25%
Revenue Per Employee	232,763
Profits Per Employee	-392,015
Employee Count	73
Asset Turnover	0.49
Inventory Turnover	4.06

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -65.74% in the last 52 weeks. The beta is 1.53, so Shield Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.53
52-Week Price Change	-65.74%
50-Day Moving Average	2.70
200-Day Moving Average	2.80
Relative Strength Index (RSI)	36.35
Average Volume (20 Days)	1,776,813

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Shield Therapeutics had revenue of GBP 16.99 million and -28.62 million in losses. Loss per share was -0.04.

Revenue	16.99M
Gross Profit	6.19M
Operating Income	-26.78M
Pretax Income	-28.53M
Net Income	-28.62M
EBITDA	-26.83M
EBIT	-26.78M
Loss Per Share	-0.04

Full Income Statement

Balance Sheet

The company has 6.41 million in cash and 15.80 million in debt, giving a net cash position of -9.39 million or -0.01 per share.

Cash & Cash Equivalents	6.41M
Total Debt	15.80M
Net Cash	-9.39M
Net Cash Per Share	-0.01
Equity (Book Value)	428,077
Book Value Per Share	0.00
Working Capital	1.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -16.45 million and capital expenditures -75,171, giving a free cash flow of -16.53 million.

Operating Cash Flow	-16.45M
Capital Expenditures	-75,171
Free Cash Flow	-16.53M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross margin is 36.44%, with operating and profit margins of -157.62% and -168.42%.

Gross Margin	36.44%
Operating Margin	-157.62%
Pretax Margin	-167.93%
Profit Margin	-168.42%
EBITDA Margin	-157.89%
EBIT Margin	-157.62%
FCF Margin	n/a

Dividends & Yields

Shield Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-59.90%
Shareholder Yield	-59.90%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Shield Therapeutics has an Altman Z-Score of -8.63. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.63
Piotroski F-Score	n/a